Literature DB >> 30108065

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Paolo Milani1,2, Stefan Schönland3, Giampaolo Merlini1,2, Christoph Kimmich3, Andrea Foli1,2, Tobias Dittrich3, Marco Basset1,2, Carsten Müller-Tidow3, Tilmann Bochtler3, Giovanni Palladini1,2, Ute Hegenbart3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30108065     DOI： 10.1182/blood-2018-04-845396

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.

Authors:  Suzanne Lentzsch; Galina G Lagos; Raymond L Comenzo; Jeffrey A Zonder; Keren Osman; Samuel Pan; Divaya Bhutani; Silva Pregja; Vaishali Sanchorawala; Heather Landau
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

Review 2.  Comprehensive Review of AL amyloidosis: some practical recommendations.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Ali Bazarbachi; Florent Malard; Jean-Luc Harousseau; Mohamad Mohty
Journal:  Blood Cancer J       Date:  2021-05-18       Impact factor: 11.037

Review 3.  Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.

Authors:  Shayna Sarosiek; Vaishali Sanchorawala
Journal:  J Blood Med       Date:  2019-10-23

Review 4.  Recent advances in the diagnosis and management of amyloid cardiomyopathy.

Authors:  Petra Nijst; Wh Wilson Tang
Journal:  Fac Rev       Date:  2021-03-24

Review 5.  AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.

Authors:  Giada Bianchi; Yifei Zhang; Raymond L Comenzo
Journal:  JACC CardioOncol       Date:  2021-10-19

6.  A Focus on Waldenström Macroglobulinemia and AL Amyloidosis.

Authors:  Rebecca Lu; Tiffany Richards
Journal:  J Adv Pract Oncol       Date:  2022-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.